No Yes Ok

Archive

Newer Entries »

LSP’s portfolio company ActoGeniX to be acquired by Intrexon Monday, February 16th, 2015
Amsterdam, the Netherlands, 13 February 2015. LSP (Life Sciences Partners), a leading European investor in health care, today announced that its portfolio company ActoGeniX, a Belgian clinical stage biopharmaceutical [...]
Merus starts Phase I/II clinical trial for MCLA-128, an ADCC-enhanced bispecific antibody for solid tumors Wednesday, February 4th, 2015
- First patient dosed in trial with potent bispecific antibody overcoming resistance to HER2-targeted therapies -   Utrecht, The Netherlands, February 4, 2015 -- Merus B.V., a leader in developing best-in-cla [...]
Hybrigenics 2014 revenues and cash Monday, February 2nd, 2015
Scientific services turnover up 3% Total operating revenues down 3% Cash position EUR 9.4 million Paris, 02 February 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Al [...]
Atlas Genetics completes $20m Series C fundraising Thursday, January 29th, 2015
Funds to accelerate global launch of Atlas io® molecular testing system Bath, UK, 29 January, 2015. Atlas Genetics Ltd (“Atlas” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnos [...]
Hybrigenics extends its partnership with Servier in the field of Ubiquitin-Specific Proteases inhibitors Monday, January 26th, 2015
Paris, 26 January 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments for proliferative diseases, tod [...]
Hybrigenics launches Phase II clinical study of inecalcitol in chronic myeloid leukemia Monday, January 19th, 2015
Paris, 19 January 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments against proliferative diseases, [...]
Prosensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer Tuesday, January 13th, 2015
Leiden, The Netherlands, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced t [...]
arGEN-X Launches Innovative Access Program Monday, January 12th, 2015
Program extends reach of proprietary SIMPLE Antibody™ platform and creates potential for future value creation   First collaborations with U.S.-based biotech company active in dyslipidemia and the de Duve I [...]
Major strategic agreement between Incyte and Agenus Friday, January 9th, 2015
Through the attached link we are happy to inform you about a major strategic agreement between Incyte and Agenus, both listed on the NASDAQ stock exchange. The Agenus programs now partnered had their origins in 4-Anti [...]
Celladon Corporation Conducts Initial Scale Up of Manufacturing Process for MYDICAR to Commercial Scale Monday, January 5th, 2015
2,000L Demonstration Batch Completed at Lonza, Houston Facility   SAN DIEGO, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading exp [...]

Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

Newer Entries »

LSP’s portfolio company ActoGeniX to be acquired by Intrexon Monday, February 16th, 2015
Amsterdam, the Netherlands, 13 February 2015. LSP (Life Sciences Partners), a leading European investor in health care, today announced that its portfolio company ActoGeniX, a Belgian clinical stage biopharmaceutical [...]
Merus starts Phase I/II clinical trial for MCLA-128, an ADCC-enhanced bispecific antibody for solid tumors Wednesday, February 4th, 2015
- First patient dosed in trial with potent bispecific antibody overcoming resistance to HER2-targeted therapies -   Utrecht, The Netherlands, February 4, 2015 -- Merus B.V., a leader in developing best-in-cla [...]
Hybrigenics 2014 revenues and cash Monday, February 2nd, 2015
Scientific services turnover up 3% Total operating revenues down 3% Cash position EUR 9.4 million Paris, 02 February 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Al [...]
Atlas Genetics completes $20m Series C fundraising Thursday, January 29th, 2015
Funds to accelerate global launch of Atlas io® molecular testing system Bath, UK, 29 January, 2015. Atlas Genetics Ltd (“Atlas” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnos [...]
Hybrigenics extends its partnership with Servier in the field of Ubiquitin-Specific Proteases inhibitors Monday, January 26th, 2015
Paris, 26 January 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments for proliferative diseases, tod [...]
Hybrigenics launches Phase II clinical study of inecalcitol in chronic myeloid leukemia Monday, January 19th, 2015
Paris, 19 January 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments against proliferative diseases, [...]
Prosensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer Tuesday, January 13th, 2015
Leiden, The Netherlands, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced t [...]
arGEN-X Launches Innovative Access Program Monday, January 12th, 2015
Program extends reach of proprietary SIMPLE Antibody™ platform and creates potential for future value creation   First collaborations with U.S.-based biotech company active in dyslipidemia and the de Duve I [...]
Major strategic agreement between Incyte and Agenus Friday, January 9th, 2015
Through the attached link we are happy to inform you about a major strategic agreement between Incyte and Agenus, both listed on the NASDAQ stock exchange. The Agenus programs now partnered had their origins in 4-Anti [...]
Celladon Corporation Conducts Initial Scale Up of Manufacturing Process for MYDICAR to Commercial Scale Monday, January 5th, 2015
2,000L Demonstration Batch Completed at Lonza, Houston Facility   SAN DIEGO, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading exp [...]

Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund